|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date29 Dec 2020 |
A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants with Advanced or Metastatic Solid Tumors
100 Clinical Results associated with Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
0 Patents (Medical) associated with Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
100 Deals associated with Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
100 Translational Medicine associated with Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.